GA 68 NETSPOT GENERATOR
GA 68 NETSPOT FULL

Neuro Endocrine Tumors, also known as NETs, are a group of tumors originating in the neuroendocrine cells of many different organs. 1 Even though NETs have historically been considered as rare tumors (orphan disease) their incidence has grown over 500% over the last 3 decades. The estimated incidence of NETs for the combined populations of the United States and the European Union is approximately 47,300 patients/year. We believe that the use of NETSPOT TM should also offer increased comfort for patients by potentially shortening a procedure that is currently performed over 24 hours or more to just a few hours.” “ NETSPOT TM has the potential to significantly improve the accuracy of NET diagnosis, while reducing radiation exposure for patients. “The FDA approval of NETSPOT TM is a key milestone in our mission of improving the lives of NET patients,” said Stefano Buono, Chief Executive Officer of AAA.

GA 68 NETSPOT GENERATOR

NETSPOT TM is currently approved for use with the GalliaPharm Ga 68 generator from Eckert & Ziegler. AAA intends to commercialize the product in the US in two forms: As a kit for reconstitution using a Ga 68 generator, and as NETSPOT TM Injection, a ready-to-use dose delivered from a local radiopharmacy in selected metropolitan areas. Gallium Ga 68 dotatate received Orphan Drug Designation from both the FDA and European Medicines Agency (EMA) in March 2014.įollowing today’s approval, NETSPOT TM will be made available to the US market as soon as possible.

NETSPOT TM is the first approved drug using Ga 68 as a positron emitter. NETSPOT TM is the new market name for Somakit-TATE (a kit for the preparation of gallium Ga 68 dotatate injection) in the US. NETSPOT TM received approval following a Priority Review from the FDA. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in molecular nuclear medicine, today announced that the US Food and Drug Administration (FDA) has approved NETSPOT TM (Somakit-TATE) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.

GA 68 NETSPOT FULL

Voiding is allowed a full bladder is not necessary.SAINT-GENIS-POUILLY, France, J(GLOBE NEWSWIRE) - Advanced Accelerator Applications S.A.For example: A 12:00 appointment would have a person drinking one glass of water at 9:00, 10:00, and 11:00.Beginning 3 hours before your scheduled exam time, drink 1 glass of water every hour, for a total of 3 glasses.Reading and phone use is allowed while in uptake.Wear comfortable clothing without metal clasps or zippers.If on a somatostatin analog such as Octreotide – please talk to your doctor as there are restrictions Anyone that accompanies the patient will be limited to the waiting area and may be allowed in patient areas at the sole discretion of the staff To ensure the safety of our patients and staff, only the patient will be allowed into the scan area. Appointment Instructions (Allow 1 ½ – 2 hours for this examination) Patients that do not show or cancel less than 24 hours prior to their appointment may be charged. Late arrivals may result in rescheduling of your scan to a later date. Please arrive 30 minutes prior to your scan time. Examination Instructions Arrival time for appointment

Ga 68 netspot